Top Markets
Coin of the day
Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA
Rang in Aktien #6654
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Aktienkurs
$6.02
Zuletzt synchronisiert: 2026-08-27
Marktkapitalisierung
$1.93B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
112.72%
Land
US
Handel Taysha Gene Therapies, Inc. (TSHA)

Kategorie

Kursverlauf für Taysha Gene Therapies, Inc. (TSHA)
Höchster Schlusskurs: $6.22 am 2026-08-01

Niedrigster Schlusskurs: $23.52 am 2020-09-01
Kursverlauf der Aktie von Taysha Gene Therapies, Inc. von 2020 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -5.89%
2025 151.61%
2024 28.42%
2023 -21.84%
2022 -83.88%
2021 -42.11%
2020 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$548.36 39.87%
US
$1.06K 50.29%
NL
$122.42 -11.85%
AU
$140.81 475.44%
US
$765.25 7.74%
CH